Chemist Warehouse
......................
ROIC vs WACC
Sigma Healthcare (ASX: SIG) has historical financial data that indicates its Return on Invested Capital (ROIC) has generally trended below or close to its Weighted Average Cost of Capital (WACC) over much of the past decade. This dynamic indicates a period of economic value destruction or neutral value creation, heavily impacted by major structural shifts, supply contract losses (such as the Chemist Warehouse contract transition in 2019), and heavy capital investments in automated distribution centers.
However, with the massive transformative merger with Chemist Warehouse progressing through 2024–2026, the company's financial profile, capital structure, and forward-looking ROIC vs. WACC metrics are undergoing radical revisions.
📊 Historical Metric Estimation (Last 10 Years)
Because precise internal hurdle rates and adjusted invested capital calculations fluctuate based on accounting methodologies (e.g., handling of lease liabilities under AASB 16), the table below highlights standard market consensus estimates for Sigma's ROIC vs. WACC over the last decade:
| Financial Year (Jan Year-End) | Estimated ROIC (%) | Estimated WACC (%) | Value Spread (ROIC - WACC) | Key Structural Driver |
|---|---|---|---|---|
| FY2016 – FY2018 | ~7.5% to 9.5% | ~7.0% to 8.0% | 🟢 Positive (+0.5% to +1.5%) | Stable wholesale operations prior to major contract shifts. |
| FY2019 – FY2021 | ~3.0% to 5.0% | ~6.5% to 7.5% | 🔴 Negative (-2.0% to -3.5%) | Loss of the core Chemist Warehouse supply contract; heavy capital expenditure into DC automation. |
| FY2022 – FY2023 | ~1.5% to 3.5% | ~7.0% to 8.0% | 🔴 Negative (-4.0% to -5.5%) | Supply chain disruptions, peak investment cycle, and compressed underlying wholesale margins. |
| FY2024 – FY2025 | ~3.5% to 5.5% | ~8.0% to 8.5% | 🔴 Negative (-3.0% to -4.5%) | Higher macroeconomic interest rates driving up WACC; initial recovery steps prior to merger execution. |
| FY2026 (Current) | Under Restructure | ~8.0% to 9.0% | In Transition | Backed by the return of the Chemist Warehouse supply contract ahead of the full corporate merger. |
🔍 Key Takeaways & Value Dynamics
- The Capital Investment Drag: Between 2018 and 2022, Sigma undertook a massive $100M+ transformation program to build highly automated distribution centers. During the construction and optimization phase, this vastly increased the denominator ("Invested Capital") while the numerator ("Net Operating Profit After Tax" or NOPAT) dipped due to contract losses, dragging ROIC well below WACC.
- The Cost of Capital (WACC) Shift: Sigma’s WACC historically hovered around 7.0% to 7.5% during the low-interest-rate environment of the 2010s. Due to global central bank tightening cycles through 2022–2024, its cost of debt and market equity risk premiums pushed its estimated WACC up to 8.0% – 9.0%.
- The Chemist Warehouse Paradigm Shift: Historical 10-year trends are backward-looking indicators for ASX:SIG. The reverse-merger style acquisition of Chemist Warehouse changes the fundamental scale of the business. The combination introduces a highly profitable retail franchise network to Sigma's low-margin infrastructure, which analysts project will substantially increase NOPAT and expand forward ROIC far above its historical baseline.
⚠️ Speculation & Loss Warning: Past performance of ROIC and WACC metrics is not a reliable indicator of future returns. Concentrated investments in companies undergoing mega-mergers carry significant execution risks, regulatory compliance friction, and capital volatility. Ensure your exposure to ASX:SIG is sized appropriately within a broadly diversified investment portfolio.
..................
PE
As of September 2026, Sigma Healthcare Ltd (ASX: SIG) trades at a Price-to-Earnings (P/E) ratio of 43.99.
Over the last 10 years, Sigma Healthcare's P/E ratio has experienced massive fluctuations, shifting from a relatively stable mid-market standard to deeply distorted or negative values due to structural transformations, major contract losses (such as the Chemist Warehouse contract transition), and its recent high-profile reverse takeover merger with Chemist Warehouse.
📊 Historical P/E Ratio Drivers & Trends (2016–2026)
Because Sigma experienced years with negative earnings (net losses) and restructures, trailing standard P/E ratios are often omitted or heavily skewed in financial databases. Below is the chronological breakdown of the valuation phases:
- 2016 – 2018 (Stable Trading Phase): The P/E ratio sat comfortably between 13x and 17x. During this period, Sigma was a steady dividend payer generating reliable wholesale distribution earnings.
- 2019 – 2022 (The Structural Shock Phase): In 2019, Sigma lost its major supply agreement with Chemist Warehouse, causing a steep drop in earnings. Non-cash impairments and restructuring costs led to statutory net losses, meaning the P/E ratio became negative / non-applicable (N/A) for several reporting periods. When underlying profits did emerge, thin margins resulted in artificially inflated, volatile P/E spikes (sometimes exceeding 60x to 80x).
- 2023 – 2024 (Speculative & Recovery Phase): As Sigma began recovering operationally and positioned itself for a massive corporate pivot, forward-looking sentiment began baking into the share price. The standard trailing P/E rose significantly, often sitting above 35x to 50x as investors valued the company on future turnaround prospects rather than depressed historical earnings.
- 2025 – 2026 (The Merger Era): Following the massive reverse-takeover deal to merge with Chemist Warehouse, Sigma's stock price surged aggressively from under $1.00 to over $2.70. This rapid capital appreciation drastically outpaced its legacy trailing earnings footprint, leaving the stock at its current highly premium trailing valuation of 43.99x.
⚠️ Speculation & Valuation Warning: Investors evaluating Sigma's current 44x P/E ratio should frame this within a structural shift context. High P/E ratios following a major merger typically reflect the market pricing in the massive consolidated revenue and earnings power of the newly combined retail pharmacy giant, rather than the standalone fundamentals of the old wholesale business.
........................................
............................
No comments:
Post a Comment